Full Breakdown
Gene-Editing Therapies for the Nervous System Still Too Early for Human Trials
8/15/2026, 6:57:38 AM
Core Event
A leading expert in brain-science commercialization warned that gene-editing approaches targeting the nervous system are not yet ready for human studies. “The techniques are reasonably well established for animal experiments, but they really haven’t been as mature for human studies,” — Karoly Nikolich. He estimated that up to five years of additional research may be required before clinical trials can begin.
Recent Fatalities Highlight Risks
The caution follows two high-profile deaths in Shanghai. A six-year-old girl with a rare genetic brain disorder died in March last year after an investigator-initiated trial injected viral particles into her spine to rewrite the mutated gene in her neurons. In a separate incident, a boy died in August last year after receiving a high dose of HuidaGene Therapeutics’ CRISPR therapy for Duchenne muscular dystrophy in a first-in-human trial.
Background & Context
Gene-editing tools such as CRISPR have been widely used in animal models to study neurological diseases, but translating these methods to humans requires careful assessment of off-target effects, immune responses, and long-term safety. In China, investigator-initiated trials (IITs) often proceed without formal drug-regulator approval, which can accelerate research but also reduces oversight.
Official Statements & Responses
Nikolich emphasized that the current scientific understanding is insufficient to predict systemic consequences of editing neuronal genes. He called for a “new round of studies” to establish safety benchmarks before any human application is attempted.
Why It Matters
If premature gene-editing therapies reach patients, severe adverse events could undermine public trust and stall the broader development of precision medicines for neurological disorders. Extended preclinical work, stricter regulatory review, and transparent reporting of trial outcomes are essential steps to ensure that future human studies are both ethical and scientifically sound.
